Results 131 to 140 of about 1,854,137 (268)

Correction: Firm, yet flexible: a fidelity debate paper with two case examples

Implementation Science
Bianca Albers, Lotte Verweij, Kathrin Blum, Saskia Oesch, Marie-Therese Schultes, Lauren Clack, Rahel Naef   +6 more
doaj   +1 more source

Correction: Matters arising: a commentary on "Failing to succeed: advancing mechanistic understanding of implementation strategies through retrospective and prospective use of causal pathway diagrams" by Austad et al. 2025. [PDF]

Implement Sci Commun
Kim B, Lewis CC.
europepmc   +1 more source

Implementing implementation science in global health

The Lancet Global Health, 2023
openaire   +2 more sources

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Outcomes of the SAEM Competency-Based Medical Education Consensus Conference: Challenges and Opportunities in Implementing CBME. [PDF]

AEM Educ Train
Hopson LR, Caretta-Weyer H, Ankel F, Cooney R, Fant A, Hall AK, Jacobson J, Kropf CW, Kulkarmi M, Lall MD, Landry A, Manella H, Parker C, Roszczynialski KN, Tanski M, Joarder A, Regan L.   +16 more
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

"The emperor's new clothes": a qualitative study of end users' experiences from a failed large-scale implementation of an electronic health record system. [PDF]

BMC Health Serv Res
Dannapfel P, Axelsson A, Gustavsson SMK.
europepmc   +1 more source

Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology

Molecular Oncology, EarlyView.
Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley   +1 more source

Gynaecology Teaching Associates in Medical Education-A Scoping Review. [PDF]

Clin Teach
Kelly C, Bell E, Brown MEL, Stelling H.
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source